帕金森病患者在脑深部电刺激手术中将周围神经移植物植入黑质:为期1年的安全性、可行性和临床结局随访研究
本研究在8例帕金森病患者行丘脑底核脑深部电刺激(DBS)手术时,将自体腓肠神经移植物单侧植入黑质,并进行12个月的安全性、可行性和临床结局评估。结果所有参与者均完成DBS系统和移植物植入,不良事件与标准DBS手术相当,仅1例腓肠神经采集部位浅表感染;停药状态下UPDRS第三部分运动评分在12个月时较基线改善(25.1±15.9分 vs 32.5±9.7分)。作者认为该操作可行且安全,移植可能有一定临床获益,值得进一步研究。
要点
- 8例帕金森病患者在DBS手术中行自体腓肠神经移植至黑质,12个月评估可行且安全。
- 不良事件与标准DBS手术相当,1例腓肠神经采集部位浅表感染,3例报告采集部位远端麻木。
- 停药状态下UPDRS第三部分运动评分12个月较基线改善,移植对侧评分降低更明显。
核心结论
- 基于该初步先导研究结果,DBS手术时将周围神经移植物植入黑质可行且安全。
- 该I期试验的临床结局数据提示移植可能有一定临床获益,值得进一步研究以确定其是否为有效且具神经修复作用的治疗。
研究设计与样本
- I期试验,8例帕金森病患者在行丘脑底核DBS手术时,将含施万细胞的自体腓肠神经移植物单侧植入黑质。
- 术前标准评估获取基线临床数据,术后1年通过临床评估、神经心理测试和MRI获取结局数据,并持续监测不良事件。
- 临床试验注册号:NCT01833364(clinicaltrials.gov)。
主要发现
- 所有8例参与者均植入DBS系统并完成神经移植。
- 不良事件与标准DBS手术相当,例外为1例腓肠神经采集部位浅表感染;3例参与者报告采集部位远端腓肠神经分布区麻木。
- 停药状态下UPDRS第三部分运动评分12个月时较基线改善(12个月均值±标准差25.1±15.9分 vs 基线32.5±9.7分)。
- 偏侧化UPDRS评分分析显示,移植对侧评分总体降低更明显。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文称该研究为初步先导研究(initial pilot study),并指出值得进一步研究以确定其是否为有效且具神经修复作用的治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVECurrently, there is no treatment that slows or halts the progression of Parkinson's disease. Delivery of various neurotrophic factors to restore dopaminergic function has become a focus of study in an effort to fill this unmet need for patients with Parkinson's disease. Schwann cells provide a readily available source of such factors. This study presents a 12-month evaluation of safety and feasibility, as well as the clinical response, of implanting autologous peripheral nerve grafts into the substantia nigra of patients with Parkinson's disease at the time of deep brain stimulation (DBS) surgery.METHODSStandard DBS surgery targeting the subthalamic nucleus was performed in 8 study participants. After DBS lead implantation, a section of the sural nerve containing Schwann cells was harvested and unilaterally grafted to the substantia nigra. Adverse events were continually monitored. Baseline clinical data were obtained during standard preoperative evaluations. Clinical outcome data were obtained with postoperative clinical evaluations, neuropsychological testing, and MRI at 1 year after surgery.RESULTSAll 8 participants were implanted with DBS systems and grafts. Adverse event profiles were comparable to those of standard DBS surgery with the exception of 1 superficial infection at the sural nerve harvest site. Three participants also reported numbness in the distribution of the sural nerve distal to the harvest site. Motor scores on Unified Parkinson's Disease Rating Scale (UPDRS) part III while the participant was off therapy at 12 months improved from baseline (mean ± SD 25.1 ± 15.9 points at 12 months vs 32.5 ± 9.7 points at baseline). An analysis of the lateralized UPDRS scores also showed a greater overall reduction in scores on the side contralateral to the graft.CONCLUSIONSPeripheral nerve graft delivery to the substantia nigra at the time of DBS surgery is feasible and safe based on the results of this initial pilot study. Clinical outcome data from this phase I trial suggests that grafting may have some clinical benefit and certainly warrants further study to determine if this is an efficacious and neurorestorative therapy.Clinical trial registration no.: NCT01833364 (clinicaltrials.gov).
引用
- van Horne CG, Quintero JE, Slevin JT, et al. Peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson's disease during deep brain stimulation surgery: 1-year follow-up study of safety, feasibility, and clinical outcome. J Neurosurg. 2018. PMID: 29451447. doi:10.3171/2017.8.JNS163222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。